7357-26-8 Usage
General Description
4-chloro-6,7-dimethoxycinnoline is a chemical compound with the molecular formula C12H10ClNO2. It is a member of the cinnoline family and is characterized by the presence of a chlorine atom and two methoxy groups on the cinnoline ring. 4-chloro-6,7-dimethoxycinnoline has potential applications in various fields, including pharmaceuticals, agrochemicals, and material science. It is known for its diverse biological activities, including anti-inflammatory, anti-cancer, and anti-bacterial properties. However, further research is needed to fully understand and exploit the potential benefits of 4-chloro-6,7-dimethoxycinnoline in these areas.
Check Digit Verification of cas no
The CAS Registry Mumber 7357-26-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,3,5 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 7357-26:
(6*7)+(5*3)+(4*5)+(3*7)+(2*2)+(1*6)=108
108 % 10 = 8
So 7357-26-8 is a valid CAS Registry Number.
7357-26-8Relevant articles and documents
Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors
Yang, Hao,Murigi, Francis N.,Wang, Zhijian,Li, Junfeng,Jin, Hongjun,Tu, Zhude
, p. 919 - 924 (2015/02/19)
Fifteen cinnoline analogues and six benzimidazole phosphodiesterase 10A (PDE10A) inhibitors were synthesized as potential PET radiopharmaceuticals and their in vitro activity as PDE10A inhibitors was determined. Nine out of twenty-one compounds were potent inhibitors of PDE10A with IC50 values ranging from 1.5 to 18.6 nM. Notably, the IC50 values of compounds 26a, 26b, and 33c were 1.52 ± 0.18, 2.86 ± 0.10, and 3.73 ± 0.60 nM, respectively; these three compounds also showed high in vitro selectivity (>1000-fold) for PDE10A over PDE 3A/3B, PDE4A/4B. The high potency and selectivity of these three compounds suggests that they could be radiolabeled with PET radionuclides for further evaluation of their in vivo pharmacological behavior and ability to quantify PDE10A in the brain.
